Scholarlink

<p>Natural products, a potent reservoir of novel anticancer compounds with fewer side effects, provide a novel treatment modality to counter challenging global cancer situations. The present study investigated the anticancer activity of the ethanolic extract of <i>Leea macrophylla</i> roots (EELM). This study employed a multivariate approach to optimize the extraction of <i>Leea macrophylla</i> tuberous roots for maximum therapeutic efficiency. Cytotoxicity assessment was performed in vitro using the MTT assay, where optimized EELM exhibited 90% and 77% cytotoxicity against HepG2 and MCF-7 cells, respectively. An Ehrlich ascites carcinoma (EAC)-induced Swiss albino mouse model was used to examine the efficacy of EELM and compared with 5-fluorouracil (5-FU). Treatment with EELM significantly reduced body weight, ascitic tumor volume, and improved the lifespan of malignant mice (<i>P</i> &lt; 0.001). After EELM, all hematological parameters returned to normal. The therapy groups had considerably less angiogenesis than the induced control group. The histopathology of significant organs showed no signs of cancer in any of the treatment groups. GC‒MS analysis of EELM revealed that its anticancer activity was attributed to the presence of 13-Octadecenoic acid, methyl ester; Methyl 10,11-octadecadienoate; Tris (tert-butyldimethylsilyloxy)arsane; and Methyl 25-methylheptacosanoate, which are found to have greater affinity towards mTOR, a key regulator of the PI3K-Akt-mTOR pathway involved in cancer progression. However, this claim needs to be validated through western blot and RT-PCR. These results establish <i>Leea macrophylla</i> as a potent anticancer agent due to its significant ability to inhibit tumors in both in vitro and in vivo cancer models.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Leea macrophylla root extract possess potential cytotoxicity in vitro against HepG2, MCF7 cells and in vivo in EAC xenografted model

  • 期刊论文

  • 发表日期：

    2025年5月21日

查看全文
  • Prafulla Kumar Sahu,
  • Roja Sahu,
  • Durga Prasad Mishra,
  • Kota Padmaja,
  • Soumya Kiran Mishra

摘要

Natural products, a potent reservoir of novel anticancer compounds with fewer side effects, provide a novel treatment modality to counter challenging global cancer situations. The present study investigated the anticancer activity of the ethanolic extract of Leea macrophylla roots (EELM). This study employed a multivariate approach to optimize the extraction of Leea macrophylla tuberous roots for maximum therapeutic efficiency. Cytotoxicity assessment was performed in vitro using the MTT assay, where optimized EELM exhibited 90% and 77% cytotoxicity against HepG2 and MCF-7 cells, respectively. An Ehrlich ascites carcinoma (EAC)-induced Swiss albino mouse model was used to examine the efficacy of EELM and compared with 5-fluorouracil (5-FU). Treatment with EELM significantly reduced body weight, ascitic tumor volume, and improved the lifespan of malignant mice (P < 0.001). After EELM, all hematological parameters returned to normal. The therapy groups had considerably less angiogenesis than the induced control group. The histopathology of significant organs showed no signs of cancer in any of the treatment groups. GC‒MS analysis of EELM revealed that its anticancer activity was attributed to the presence of 13-Octadecenoic acid, methyl ester; Methyl 10,11-octadecadienoate; Tris (tert-butyldimethylsilyloxy)arsane; and Methyl 25-methylheptacosanoate, which are found to have greater affinity towards mTOR, a key regulator of the PI3K-Akt-mTOR pathway involved in cancer progression. However, this claim needs to be validated through western blot and RT-PCR. These results establish Leea macrophylla as a potent anticancer agent due to its significant ability to inhibit tumors in both in vitro and in vivo cancer models.

Graphical Abstract